Kemwell’s Bangalore Facility Completes Successful FDA Inspection
PTSM: Pharmaceutical Technology Sourcing and Management
FDA has concluded that Kemwell’s facility, systems, and practices comply with FDA’s requirements and no observations were reported on Form 483.
CDMO, Kemwell, announced that its oral solid dosage manufacturing facility in Bangalore, India has successfully completed a second FDA inspection. The facility was audited following an abbreviated new drug application (ANDA) filing for a customer. The FDA inspector has concluded that Kemwell’s facility, systems, and practices comply with FDA’s requirements and no observations were reported on Form 483.
Production in the state-of-the-art oral solid dosage facility commenced in 2008. The facility, which is equipped to manage batch sizes ranging from 10–1000 kg, manufactures five billion tablets and capsules annually according to Kemwell. The company has been shipping products from this facility to Europe, US, Canada, and Australia.
Source: Kemwell
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
